AngioDynamics, Inc. (ANGO) 10-Year Financial Performance & Capital Metrics

ANGO • • Industrial / General

HealthcareMedical InstrumentsSurgical & Interventional DevicesCardiac & Vascular Intervention

AboutAngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides endovascular therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies that are used primarily to deliver short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.Show more

Revenue $292M -3.8%
EBITDA -$14M +91.4%
Net Income -$34M +81.6%
EPS (Diluted) -0.83 +81.9%
Gross Margin 53.92% +5.9%
EBITDA Margin -4.84% +91.1%
Operating Margin -13.66% +78.4%
Net Margin -11.62% +80.8%
ROE -17.5% +72.3%
ROIC -22.93% +57.7%
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Efficient asset utilization: 1.0x turnover

✗Weaknesses

✗Negative free cash flow
✗Low quality earnings: Net income not backed by cash flow

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-1.97%

5Y2.06%

3Y-2.57%

TTM7.26%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM87.67%

EPS CAGR

10Y-

5Y-

3Y-

TTM87.97%

ROCE

10Y Avg-12.98%

5Y Avg-19.82%

3Y Avg-28.86%

Latest-18.56%

Peer Comparison

Cardiac & Vascular Intervention

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
LMATLeMaitre Vascular, Inc.	1.96B	86.50	44.82	13.63%	22.14%	14.08%	1.89%	0.55
MMSIMerit Medical Systems, Inc.	4.76B	80.35	39.58	7.89%	8.02%	7.74%	3.84%	0.58
ANGOAngioDynamics, Inc.	453.8M	11.01	-13.27	-3.76%	-9.02%	-15.71%
ATRCAtriCure, Inc.	2.06B	41.46	-43.64	16.55%	-5.55%	-6.04%		0.17

Profit & Loss

	May 2016	May 2017	May 2018	May 2019	May 2020	May 2021	May 2022	May 2023	May 2024	May 2025
Sales/Revenue+	353.69M	349.64M	344.29M	359.48M	264.16M	291.01M	316.22M	338.75M	303.91M	292.5M
Revenue Growth %	-0.01%	-0.01%	-0.02%	0.04%	-0.27%	0.1%	0.09%	0.07%	-0.1%	-0.04%
Cost of Goods Sold+	179.57M	125.84M	117.8M	114.63M	113.89M	134.22M	150.49M	164.51M	149.22M	134.79M
COGS % of Revenue	0.51%	0.36%	0.34%	0.32%	0.43%	0.46%	0.48%	0.49%	0.49%	0.46%
Gross Profit+	174.32M	143.95M	143.86M	156M	150.27M	156.79M	165.73M	174.25M	154.7M	157.71M
Gross Margin %	0.49%	0.41%	0.42%	0.43%	0.57%	0.54%	0.52%	0.51%	0.51%	0.54%
Gross Profit Growth %	-0.01%	-0.17%	-0%	0.08%	-0.04%	0.04%	0.06%	0.05%	-0.11%	0.02%
Operating Expenses+	173.3M	155.13M	158.03M	165.4M	317.37M	192.07M	194.2M	225.43M	347.13M	197.66M
OpEx % of Revenue	0.49%	0.44%	0.46%	0.46%	1.2%	0.66%	0.61%	0.67%	1.14%	0.68%
Selling, General & Admin	114.12M	110.22M	108.54M	116.13M	116.51M	117.22M	133.75M	144.25M	143.98M	145.23M
SG&A % of Revenue	0.32%	0.32%	0.32%	0.32%	0.44%	0.4%	0.42%	0.43%	0.47%	0.5%
Research & Development	25.13M	25.27M	25.46M	29.43M	29.68M	36.39M	30.74M	29.88M	31.51M	26.22M
R&D % of Revenue	0.07%	0.07%	0.07%	0.08%	0.11%	0.13%	0.1%	0.09%	0.1%	0.09%
Other Operating Expenses	33.92M	24.98M	29.59M	25.41M	171.18M	38.46M	29.71M	51.29M	171.64M	26.21M
Operating Income+	1.02M	-11.18M	-14.17M	-9.4M	-167.1M	-35.28M	-28.47M	-51.18M	-192.44M	-39.95M
Operating Margin %	0%	-0.03%	-0.04%	-0.03%	-0.63%	-0.12%	-0.09%	-0.15%	-0.63%	-0.14%
Operating Income Growth %	1.3%	-11.98%	-0.27%	0.34%	-16.78%	0.79%	0.19%	-0.8%	-2.76%	0.79%
EBITDA+	29.13M	13.64M	8.99M	16.48M	-143.29M	-9.37M	878K	-20.31M	-164.72M	-14.15M
EBITDA Margin %	0.08%	0.04%	0.03%	0.05%	-0.54%	-0.03%	0%	-0.06%	-0.54%	-0.05%
EBITDA Growth %	0.1%	-0.53%	-0.34%	0.83%	-9.69%	0.93%	1.09%	-24.13%	-7.11%	0.91%
D&A (Non-Cash Add-back)	28.11M	24.81M	23.16M	25.88M	23.8M	25.92M	29.35M	30.87M	27.71M	25.8M
EBIT	132K	-11.46M	-14.2M	-9.6M	-167.23M	-35.19M	-18.22M	-18.68M	-33.84M	-24.06M
Net Interest Income+	-3.38M	-2.84M	-3.06M	-5.1M	-907K	-861K	-688K	-2.7M	1.61M	978K
Interest Income	11K	0	0	0	0	0	0	0	1.61M	978K
Interest Expense	3.4M	2.84M	3.06M	5.1M	907K	861K	688K	2.7M	0	0
Other Income/Expense	-4.27M	-3.12M	-3.09M	-5.31M	-1.04M	-769K	-1.48M	-3.26M	797K	5.92M
Pretax Income+	-3.25M	-14.29M	-17.26M	-14.7M	-168.13M	-36.05M	-29.95M	-54.44M	-191.64M	-34.03M
Pretax Margin %	-0.01%	-0.04%	-0.05%	-0.04%	-0.64%	-0.12%	-0.09%	-0.16%	-0.63%	-0.12%
Income Tax+	40.34M	-7.24M	-11.04M	-3.56M	-1.35M	-4.5M	-3.4M	-2M	-7.29M	-39K
Effective Tax Rate %	13.4%	0.49%	-0.95%	-4.17%	0.99%	0.88%	0.89%	0.96%	0.96%	1%
Net Income+	-43.59M	-7.05M	16.34M	61.34M	-166.79M	-31.55M	-26.55M	-52.44M	-184.35M	-33.99M
Net Margin %	-0.12%	-0.02%	0.05%	0.17%	-0.63%	-0.11%	-0.08%	-0.15%	-0.61%	-0.12%
Net Income Growth %	-11.87%	0.84%	3.32%	2.76%	-3.72%	0.81%	0.16%	-0.98%	-2.52%	0.82%
Net Income (Continuing)	-43.59M	-7.05M	-6.23M	-11.15M	-166.79M	-31.55M	-26.55M	-52.44M	-184.35M	-33.99M
Discontinued Operations	0	0	22.56M	72.49M	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-1.23	0.19	0.44	1.64	-4.37	-0.82	-0.68	-1.33	-4.59	-0.83
EPS Growth %	-12.43%	1.15%	1.32%	2.73%	-3.66%	0.81%	0.17%	-0.96%	-2.45%	0.82%
EPS (Basic)	-1.23	0.19	0.44	1.64	-4.37	-0.82	-0.68	-1.33	-4.59	-0.83
Diluted Shares Outstanding	36.16M	36.96M	37.54M	37.48M	37.96M	38.34M	39.01M	39.48M	40.18M	40.98M
Basic Shares Outstanding	36.02M	36.62M	37.08M	37.48M	37.96M	38.34M	39.01M	39.48M	40.18M	40.98M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	May 2016	May 2017	May 2018	May 2019	May 2020	May 2021	May 2022	May 2023	May 2024	May 2025
Total Current Assets+	146.25M	153.91M	168.03M	315.29M	152.91M	140.88M	143.34M	163.54M	193.25M	168.32M
Cash & Short-Term Investments	33.99M	48.76M	75.41M	227.64M	54.44M	48.16M	28.82M	44.62M	76.06M	55.89M
Cash Only	32.33M	47.54M	74.1M	227.64M	54.44M	48.16M	28.82M	44.62M	76.06M	55.89M
Short-Term Investments	1.65M	1.22M	1.32M	0	0	0	0	0	0	0
Accounts Receivable	52.87M	46.36M	39.4M	43.58M	34.17M	37.32M	56.5M	52.83M	50.01M	43.14M
Days Sales Outstanding	54.56	48.4	41.77	44.25	47.22	46.8	65.21	56.92	60.06	53.83
Inventory	55.37M	54.51M	39.27M	40.07M	59.91M	48.61M	51.39M	55.33M	60.62M	62.01M
Days Inventory Outstanding	112.54	158.1	121.69	127.59	191.99	132.2	124.65	122.75	148.27	167.9
Other Current Assets	2.29M	2.76M	12.15M	2.2M	1.55M	1.76M	2.2M	7.26M	2.58M	3.07M
Total Non-Current Assets+	581.81M	554.05M	537.44M	521.15M	442.6M	420.56M	409.41M	369.1M	124.42M	111.82M
Property, Plant & Equipment	48.28M	45.23M	25.71M	24.26M	28.31M	37.07M	45.01M	44.38M	35.67M	32.3M
Fixed Asset Turnover	7.33x	7.73x	13.39x	14.82x	9.33x	7.85x	7.03x	7.63x	8.52x	9.06x
Goodwill	361.25M	361.25M	361.25M	347.67M	201.51M	201.32M	201.06M	159.24M	0	0
Intangible Assets	167.58M	145.68M	130.31M	145.39M	197.14M	168.98M	152.38M	111.14M	77.38M	69.12M
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	3.83M	1.89M	113.23M	3.83M	15.64M	13.19M	10.96M	54.33M	11.37M	10.4M
Total Assets+	728.06M	707.96M	705.47M	836.44M	595.51M	561.44M	552.75M	532.64M	317.67M	280.14M
Asset Turnover	0.49x	0.49x	0.49x	0.43x	0.44x	0.52x	0.57x	0.64x	0.96x	1.04x
Asset Growth %	-0.06%	-0.03%	-0%	0.19%	-0.29%	-0.06%	-0.02%	-0.04%	-0.4%	-0.12%
Total Current Liabilities+	67.1M	69.52M	57.3M	73.3M	51.53M	57.58M	74.32M	83.83M	91.16M	76.2M
Accounts Payable	15.62M	18.09M	15.78M	22.83M	19.1M	19.63M	28.05M	40.45M	37.75M	33.29M
Days Payables Outstanding	31.74	52.46	48.88	72.69	61.2	53.38	68.03	89.74	92.34	90.15
Short-Term Debt	29.17M	14.63M	7.1M	12.13M	836K	0	8.78M	14.76M	4.73M	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	1.52M	2.08M	1.94M	504K	3.02M	3.04M	2.71M	2.26M	9.06M	8.56M
Current Ratio	2.18x	2.21x	2.93x	4.30x	2.97x	2.45x	1.93x	1.95x	2.12x	2.21x
Quick Ratio	1.35x	1.43x	2.25x	3.75x	1.80x	1.60x	1.24x	1.29x	1.46x	1.40x
Cash Conversion Cycle	135.36	154.03	114.58	99.14	178.01	125.62	121.84	89.93	115.99	131.59
Total Non-Current Liabilities+	153.94M	121.42M	105.58M	148.32M	88.11M	64.4M	53.94M	70.52M	20.93M	20.98M
Long-Term Debt	104.29M	91.32M	86.62M	124.41M	40M	20M	25M	49.82M	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	21.68M	26.11M	17.17M	14.54M	24.06M	19.95M	16.04M	12.81M	4.85M	4.07M
Other Non-Current Liabilities	26.26M	3.99M	1.78M	9.37M	23.84M	24.44M	12.9M	7.88M	16.08M	16.9M
Total Liabilities	221.04M	190.93M	162.88M	221.62M	139.64M	121.98M	128.26M	154.34M	112.08M	97.17M
Total Debt+	133.46M	105.94M	93.72M	136.54M	40.84M	20M	33.78M	64.58M	4.73M	0
Net Debt	101.13M	58.4M	19.63M	-91.1M	-13.6M	-28.16M	4.96M	19.96M	-71.33M	-55.89M
Debt / Equity	0.26x	0.20x	0.17x	0.22x	0.09x	0.05x	0.08x	0.17x	0.02x	-
Debt / EBITDA	4.58x	7.77x	10.42x	8.28x	-	-	38.48x	-	-	-
Net Debt / EBITDA	3.47x	4.28x	2.18x	-5.53x	-	-	5.65x	-	-	-
Interest Coverage	0.30x	-3.94x	-4.63x	-1.84x	-184.23x	-40.98x	-41.38x	-18.94x	-	-
Total Equity+	507.03M	517.03M	542.6M	614.82M	455.87M	439.46M	424.49M	378.3M	205.59M	182.97M
Equity Growth %	-0.07%	0.02%	0.05%	0.13%	-0.26%	-0.04%	-0.03%	-0.11%	-0.46%	-0.11%
Book Value per Share	14.02	13.99	14.45	16.40	12.01	11.46	10.88	9.58	5.12	4.46
Total Shareholders' Equity	507.03M	517.03M	542.6M	614.82M	455.87M	439.46M	424.49M	378.3M	205.59M	182.97M
Common Stock	363K	367K	370K	372K	374K	377K	380K	382K	385K	385K
Retained Earnings	-16.02M	-11.01M	5.13M	66.47M	-100.32M	-131.87M	-158.41M	-210.85M	-395.2M	-429.2M
Treasury Stock	-2.1M	-5.71M	-5.71M	-5.71M	-5.71M	-5.71M	-5.71M	-5.71M	-5.71M	-7.38M
Accumulated OCI	-791K	-1.32M	-952K	-1.35M	-1.34M	3.15M	1.36M	-4.72M	-4.37M	-2.02M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	May 2016	May 2017	May 2018	May 2019	May 2020	May 2021	May 2022	May 2023	May 2024	May 2025
Cash from Operations+	45.22M	55.74M	41.29M	37.44M	-14.55M	24.09M	-7.19M	78K	-28.16M	-10.13M
Operating CF Margin %	0.13%	0.16%	0.12%	0.1%	-0.06%	0.08%	-0.02%	0%	-0.09%	-0.03%
Operating CF Growth %	0.76%	0.23%	-0.26%	-0.09%	-1.39%	2.66%	-1.3%	1.01%	-362%	0.64%
Net Income	-44.45M	7.01M	16.34M	61.34M	-156.07M	-31.55M	-26.55M	-52.44M	-184.35M	-33.99M
Depreciation & Amortization	28.38M	24.81M	23.16M	25.88M	23.8M	25.92M	29.35M	30.87M	27.71M	25.8M
Stock-Based Compensation	3.24M	6.18M	7.91M	9.25M	7.59M	8.63M	10.69M	11.16M	10.53M	9.77M
Deferred Taxes	39.98M	4.43M	-8.95M	-2.65M	-1.57M	-4.8M	-3.71M	-2.31M	-7.97M	-988K
Other Non-Cash Items	4.61M	-9.54M	364K	-55.11M	140.23M	16.83M	4.07M	19.83M	111.5M	3.39M
Working Capital Changes	12.86M	24.86M	2.46M	-1.26M	-28.55M	9.07M	-21.05M	-7.03M	14.42M	-14.11M
Change in Receivables	3.13M	8.48M	5.04M	-3.18M	11.92M	-4.16M	-17.15M	-1.3M	7.89M	23K
Change in Inventory	11.98M	687K	5.74M	-1.43M	-18.84M	11.54M	-2.8M	-8.2M	-9.41M	-1.35M
Change in Payables	-3.4M	17.21M	-7.09M	5.21M	-15.47M	4.88M	3.91M	2.14M	27.53M	-15.88M
Cash from Investing+	-7.57M	-2.55M	-3.66M	82.55M	-63.34M	-13.71M	-19.31M	-9.75M	123.72M	-10.18M
Capital Expenditures	-2.33M	-3M	-2.39M	-3.12M	-7.24M	-5.19M	-4.3M	-3.81M	-2.52M	-4.46M
CapEx % of Revenue	0.01%	0.01%	0.01%	0.01%	0.03%	0.02%	0.01%	0.01%	0.01%	0.02%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-3.27M	0	-1.26M	169.24M	-350K	-8.52M	-11.41M	-5.93M	126.23M	-5.71M
Cash from Financing+	-23.66M	-37.98M	-11.55M	33.93M	-95.24M	-16.99M	7.68M	25.42M	-64.25M	-255K
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-7.41M	-516K	-6.55M	-6.07M	-2.74M	0	0	-751K	-15M	-4.75M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	39.62M	52.74M	37.63M	34.32M	-22.14M	18.91M	-11.49M	-4.27M	-33.93M	-14.59M
FCF Margin %	0.11%	0.15%	0.11%	0.1%	-0.08%	0.06%	-0.04%	-0.01%	-0.11%	-0.05%
FCF Growth %	2.06%	0.33%	-0.29%	-0.09%	-1.65%	1.85%	-1.61%	0.63%	-6.94%	0.57%
FCF per Share	1.10	1.43	1.00	0.92	-0.58	0.49	-0.29	-0.11	-0.84	-0.36
FCF Conversion (FCF/Net Income)	-1.04x	-7.90x	2.53x	0.61x	0.09x	-0.76x	0.27x	-0.00x	0.15x	0.30x
Interest Paid	3.06M	2.97M	3.19M	5.12M	413K	731K	562K	2.58M	0	185K
Taxes Paid	332K	102K	36K	426K	682K	313K	329K	342K	455K	800K

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-8.29%	-1.38%	3.08%	10.6%	-31.16%	-7.05%	-6.15%	-13.06%	-63.15%	-17.5%
Return on Invested Capital (ROIC)	0.12%	-1.42%	-1.87%	-1.3%	-25.95%	-6.2%	-5.08%	-9.28%	-54.21%	-22.93%
Gross Margin	49.29%	41.17%	41.78%	43.4%	56.89%	53.88%	52.41%	51.44%	50.9%	53.92%
Net Margin	-12.32%	-2.02%	4.74%	17.06%	-63.14%	-10.84%	-8.4%	-15.48%	-60.66%	-11.62%
Debt / Equity	0.26x	0.20x	0.17x	0.22x	0.09x	0.05x	0.08x	0.17x	0.02x	-
Interest Coverage	0.30x	-3.94x	-4.63x	-1.84x	-184.23x	-40.98x	-41.38x	-18.94x	-	-
FCF Conversion	-1.04x	-7.90x	2.53x	0.61x	0.09x	-0.76x	0.27x	-0.00x	0.15x	0.30x
Revenue Growth	-0.92%	-1.14%	-1.53%	4.41%	-26.52%	10.17%	8.66%	7.13%	-10.28%	-3.76%

Revenue by Segment

	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Med Device	-	-	-	-	-	-	237.5M	-	197.51M	-
Med Device Growth	-	-	-	-	-	-	-	-	-	-
Med Tech	-	-	-	-	-	-	78.72M	-	106.4M	-
Med Tech Growth	-	-	-	-	-	-	-	-	-	-
Endovascular Therapies	-	-	-	-	-	135.08M	-	-	-	-
Endovascular Therapies Growth	-	-	-	-	-	-	-	-	-	-
Oncology Surgery	48.9M	44.56M	49.19M	-	57.15M	54.62M	-	-	-	-
Oncology Surgery Growth	-	-8.87%	10.39%	-	-	-4.43%	-	-	-	-
Peripheral Vascular	202.78M	208.6M	202.33M	-	112.71M	-	-	-	-	-
Peripheral Vascular Growth	-	2.87%	-3.00%	-	-	-	-	-	-	-
Access	99.38M	96.48M	92.76M	94.73M	94.3M	-	-	-	-	-
Access Growth	-	-2.91%	-3.86%	2.12%	-0.45%	-	-	-	-	-
Supply Agreement	2.84M	-	-	-	-	-	-	-	-	-
Supply Agreement Growth	-	-	-	-	-	-	-	-	-	-

Revenue by Geography

	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
UNITED STATES	283.52M	282.17M	273.33M	106.77M	98.97M	121.43M	146.88M	84.33M	251.49M	250.98M
UNITED STATES Growth	-	-0.48%	-3.13%	-60.94%	-7.31%	22.70%	20.96%	-42.58%	198.21%	-0.20%
International	-	-	-	-	-	-	-	-	52.43M	41.52M
International Growth	-	-	-	-	-	-	-	-	-	-20.82%
Non-US	-	-	-	13.13M	13.74M	13.65M	14.04M	12.36M	-	-
Non-US Growth	-	-	-	-	4.62%	-0.65%	2.87%	-12.03%	-	-

Frequently Asked Questions

Growth & Financials

AngioDynamics, Inc. (ANGO) reported $307.3M in revenue for fiscal year 2025. This represents a 39% increase from $221.8M in 2012.

AngioDynamics, Inc. (ANGO) saw revenue decline by 3.8% over the past year.

AngioDynamics, Inc. (ANGO) reported a net loss of $27.7M for fiscal year 2025.

Dividend & Returns

AngioDynamics, Inc. (ANGO) has a return on equity (ROE) of -17.5%. Negative ROE indicates the company is unprofitable.

AngioDynamics, Inc. (ANGO) had negative free cash flow of $9.3M in fiscal year 2025, likely due to heavy capital investments.

US Stock Screener

...

AngioDynamics, Inc. (ANGO) 10-Year Financial Performance & Capital Metrics

ANGO • • Industrial / General

HealthcareMedical InstrumentsSurgical & Interventional DevicesCardiac & Vascular Intervention

Revenue $292M -3.8%
EBITDA -$14M +91.4%
Net Income -$34M +81.6%
EPS (Diluted) -0.83 +81.9%
Gross Margin 53.92% +5.9%
EBITDA Margin -4.84% +91.1%
Operating Margin -13.66% +78.4%
Net Margin -11.62% +80.8%
ROE -17.5% +72.3%
ROIC -22.93% +57.7%
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Efficient asset utilization: 1.0x turnover

✗Weaknesses

✗Negative free cash flow
✗Low quality earnings: Net income not backed by cash flow

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-1.97%

5Y2.06%

3Y-2.57%

TTM7.26%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM87.67%

EPS CAGR

10Y-

5Y-

3Y-

TTM87.97%

ROCE

10Y Avg-12.98%

5Y Avg-19.82%

3Y Avg-28.86%

Latest-18.56%

Peer Comparison

Cardiac & Vascular Intervention

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
LMATLeMaitre Vascular, Inc.	1.96B	86.50	44.82	13.63%	22.14%	14.08%	1.89%	0.55
MMSIMerit Medical Systems, Inc.	4.76B	80.35	39.58	7.89%	8.02%	7.74%	3.84%	0.58
ANGOAngioDynamics, Inc.	453.8M	11.01	-13.27	-3.76%	-9.02%	-15.71%
ATRCAtriCure, Inc.	2.06B	41.46	-43.64	16.55%	-5.55%	-6.04%		0.17

Profit & Loss

	May 2016	May 2017	May 2018	May 2019	May 2020	May 2021	May 2022	May 2023	May 2024	May 2025
Sales/Revenue+	353.69M	349.64M	344.29M	359.48M	264.16M	291.01M	316.22M	338.75M	303.91M	292.5M
Revenue Growth %	-0.01%	-0.01%	-0.02%	0.04%	-0.27%	0.1%	0.09%	0.07%	-0.1%	-0.04%
Cost of Goods Sold+	179.57M	125.84M	117.8M	114.63M	113.89M	134.22M	150.49M	164.51M	149.22M	134.79M
COGS % of Revenue	0.51%	0.36%	0.34%	0.32%	0.43%	0.46%	0.48%	0.49%	0.49%	0.46%
Gross Profit+	174.32M	143.95M	143.86M	156M	150.27M	156.79M	165.73M	174.25M	154.7M	157.71M
Gross Margin %	0.49%	0.41%	0.42%	0.43%	0.57%	0.54%	0.52%	0.51%	0.51%	0.54%
Gross Profit Growth %	-0.01%	-0.17%	-0%	0.08%	-0.04%	0.04%	0.06%	0.05%	-0.11%	0.02%
Operating Expenses+	173.3M	155.13M	158.03M	165.4M	317.37M	192.07M	194.2M	225.43M	347.13M	197.66M
OpEx % of Revenue	0.49%	0.44%	0.46%	0.46%	1.2%	0.66%	0.61%	0.67%	1.14%	0.68%
Selling, General & Admin	114.12M	110.22M	108.54M	116.13M	116.51M	117.22M	133.75M	144.25M	143.98M	145.23M
SG&A % of Revenue	0.32%	0.32%	0.32%	0.32%	0.44%	0.4%	0.42%	0.43%	0.47%	0.5%
Research & Development	25.13M	25.27M	25.46M	29.43M	29.68M	36.39M	30.74M	29.88M	31.51M	26.22M
R&D % of Revenue	0.07%	0.07%	0.07%	0.08%	0.11%	0.13%	0.1%	0.09%	0.1%	0.09%
Other Operating Expenses	33.92M	24.98M	29.59M	25.41M	171.18M	38.46M	29.71M	51.29M	171.64M	26.21M
Operating Income+	1.02M	-11.18M	-14.17M	-9.4M	-167.1M	-35.28M	-28.47M	-51.18M	-192.44M	-39.95M
Operating Margin %	0%	-0.03%	-0.04%	-0.03%	-0.63%	-0.12%	-0.09%	-0.15%	-0.63%	-0.14%
Operating Income Growth %	1.3%	-11.98%	-0.27%	0.34%	-16.78%	0.79%	0.19%	-0.8%	-2.76%	0.79%
EBITDA+	29.13M	13.64M	8.99M	16.48M	-143.29M	-9.37M	878K	-20.31M	-164.72M	-14.15M
EBITDA Margin %	0.08%	0.04%	0.03%	0.05%	-0.54%	-0.03%	0%	-0.06%	-0.54%	-0.05%
EBITDA Growth %	0.1%	-0.53%	-0.34%	0.83%	-9.69%	0.93%	1.09%	-24.13%	-7.11%	0.91%
D&A (Non-Cash Add-back)	28.11M	24.81M	23.16M	25.88M	23.8M	25.92M	29.35M	30.87M	27.71M	25.8M
EBIT	132K	-11.46M	-14.2M	-9.6M	-167.23M	-35.19M	-18.22M	-18.68M	-33.84M	-24.06M
Net Interest Income+	-3.38M	-2.84M	-3.06M	-5.1M	-907K	-861K	-688K	-2.7M	1.61M	978K
Interest Income	11K	0	0	0	0	0	0	0	1.61M	978K
Interest Expense	3.4M	2.84M	3.06M	5.1M	907K	861K	688K	2.7M	0	0
Other Income/Expense	-4.27M	-3.12M	-3.09M	-5.31M	-1.04M	-769K	-1.48M	-3.26M	797K	5.92M
Pretax Income+	-3.25M	-14.29M	-17.26M	-14.7M	-168.13M	-36.05M	-29.95M	-54.44M	-191.64M	-34.03M
Pretax Margin %	-0.01%	-0.04%	-0.05%	-0.04%	-0.64%	-0.12%	-0.09%	-0.16%	-0.63%	-0.12%
Income Tax+	40.34M	-7.24M	-11.04M	-3.56M	-1.35M	-4.5M	-3.4M	-2M	-7.29M	-39K
Effective Tax Rate %	13.4%	0.49%	-0.95%	-4.17%	0.99%	0.88%	0.89%	0.96%	0.96%	1%
Net Income+	-43.59M	-7.05M	16.34M	61.34M	-166.79M	-31.55M	-26.55M	-52.44M	-184.35M	-33.99M
Net Margin %	-0.12%	-0.02%	0.05%	0.17%	-0.63%	-0.11%	-0.08%	-0.15%	-0.61%	-0.12%
Net Income Growth %	-11.87%	0.84%	3.32%	2.76%	-3.72%	0.81%	0.16%	-0.98%	-2.52%	0.82%
Net Income (Continuing)	-43.59M	-7.05M	-6.23M	-11.15M	-166.79M	-31.55M	-26.55M	-52.44M	-184.35M	-33.99M
Discontinued Operations	0	0	22.56M	72.49M	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-1.23	0.19	0.44	1.64	-4.37	-0.82	-0.68	-1.33	-4.59	-0.83
EPS Growth %	-12.43%	1.15%	1.32%	2.73%	-3.66%	0.81%	0.17%	-0.96%	-2.45%	0.82%
EPS (Basic)	-1.23	0.19	0.44	1.64	-4.37	-0.82	-0.68	-1.33	-4.59	-0.83
Diluted Shares Outstanding	36.16M	36.96M	37.54M	37.48M	37.96M	38.34M	39.01M	39.48M	40.18M	40.98M
Basic Shares Outstanding	36.02M	36.62M	37.08M	37.48M	37.96M	38.34M	39.01M	39.48M	40.18M	40.98M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	May 2016	May 2017	May 2018	May 2019	May 2020	May 2021	May 2022	May 2023	May 2024	May 2025
Total Current Assets+	146.25M	153.91M	168.03M	315.29M	152.91M	140.88M	143.34M	163.54M	193.25M	168.32M
Cash & Short-Term Investments	33.99M	48.76M	75.41M	227.64M	54.44M	48.16M	28.82M	44.62M	76.06M	55.89M
Cash Only	32.33M	47.54M	74.1M	227.64M	54.44M	48.16M	28.82M	44.62M	76.06M	55.89M
Short-Term Investments	1.65M	1.22M	1.32M	0	0	0	0	0	0	0
Accounts Receivable	52.87M	46.36M	39.4M	43.58M	34.17M	37.32M	56.5M	52.83M	50.01M	43.14M
Days Sales Outstanding	54.56	48.4	41.77	44.25	47.22	46.8	65.21	56.92	60.06	53.83
Inventory	55.37M	54.51M	39.27M	40.07M	59.91M	48.61M	51.39M	55.33M	60.62M	62.01M
Days Inventory Outstanding	112.54	158.1	121.69	127.59	191.99	132.2	124.65	122.75	148.27	167.9
Other Current Assets	2.29M	2.76M	12.15M	2.2M	1.55M	1.76M	2.2M	7.26M	2.58M	3.07M
Total Non-Current Assets+	581.81M	554.05M	537.44M	521.15M	442.6M	420.56M	409.41M	369.1M	124.42M	111.82M
Property, Plant & Equipment	48.28M	45.23M	25.71M	24.26M	28.31M	37.07M	45.01M	44.38M	35.67M	32.3M
Fixed Asset Turnover	7.33x	7.73x	13.39x	14.82x	9.33x	7.85x	7.03x	7.63x	8.52x	9.06x
Goodwill	361.25M	361.25M	361.25M	347.67M	201.51M	201.32M	201.06M	159.24M	0	0
Intangible Assets	167.58M	145.68M	130.31M	145.39M	197.14M	168.98M	152.38M	111.14M	77.38M	69.12M
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	3.83M	1.89M	113.23M	3.83M	15.64M	13.19M	10.96M	54.33M	11.37M	10.4M
Total Assets+	728.06M	707.96M	705.47M	836.44M	595.51M	561.44M	552.75M	532.64M	317.67M	280.14M
Asset Turnover	0.49x	0.49x	0.49x	0.43x	0.44x	0.52x	0.57x	0.64x	0.96x	1.04x
Asset Growth %	-0.06%	-0.03%	-0%	0.19%	-0.29%	-0.06%	-0.02%	-0.04%	-0.4%	-0.12%
Total Current Liabilities+	67.1M	69.52M	57.3M	73.3M	51.53M	57.58M	74.32M	83.83M	91.16M	76.2M
Accounts Payable	15.62M	18.09M	15.78M	22.83M	19.1M	19.63M	28.05M	40.45M	37.75M	33.29M
Days Payables Outstanding	31.74	52.46	48.88	72.69	61.2	53.38	68.03	89.74	92.34	90.15
Short-Term Debt	29.17M	14.63M	7.1M	12.13M	836K	0	8.78M	14.76M	4.73M	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	1.52M	2.08M	1.94M	504K	3.02M	3.04M	2.71M	2.26M	9.06M	8.56M
Current Ratio	2.18x	2.21x	2.93x	4.30x	2.97x	2.45x	1.93x	1.95x	2.12x	2.21x
Quick Ratio	1.35x	1.43x	2.25x	3.75x	1.80x	1.60x	1.24x	1.29x	1.46x	1.40x
Cash Conversion Cycle	135.36	154.03	114.58	99.14	178.01	125.62	121.84	89.93	115.99	131.59
Total Non-Current Liabilities+	153.94M	121.42M	105.58M	148.32M	88.11M	64.4M	53.94M	70.52M	20.93M	20.98M
Long-Term Debt	104.29M	91.32M	86.62M	124.41M	40M	20M	25M	49.82M	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	21.68M	26.11M	17.17M	14.54M	24.06M	19.95M	16.04M	12.81M	4.85M	4.07M
Other Non-Current Liabilities	26.26M	3.99M	1.78M	9.37M	23.84M	24.44M	12.9M	7.88M	16.08M	16.9M
Total Liabilities	221.04M	190.93M	162.88M	221.62M	139.64M	121.98M	128.26M	154.34M	112.08M	97.17M
Total Debt+	133.46M	105.94M	93.72M	136.54M	40.84M	20M	33.78M	64.58M	4.73M	0
Net Debt	101.13M	58.4M	19.63M	-91.1M	-13.6M	-28.16M	4.96M	19.96M	-71.33M	-55.89M
Debt / Equity	0.26x	0.20x	0.17x	0.22x	0.09x	0.05x	0.08x	0.17x	0.02x	-
Debt / EBITDA	4.58x	7.77x	10.42x	8.28x	-	-	38.48x	-	-	-
Net Debt / EBITDA	3.47x	4.28x	2.18x	-5.53x	-	-	5.65x	-	-	-
Interest Coverage	0.30x	-3.94x	-4.63x	-1.84x	-184.23x	-40.98x	-41.38x	-18.94x	-	-
Total Equity+	507.03M	517.03M	542.6M	614.82M	455.87M	439.46M	424.49M	378.3M	205.59M	182.97M
Equity Growth %	-0.07%	0.02%	0.05%	0.13%	-0.26%	-0.04%	-0.03%	-0.11%	-0.46%	-0.11%
Book Value per Share	14.02	13.99	14.45	16.40	12.01	11.46	10.88	9.58	5.12	4.46
Total Shareholders' Equity	507.03M	517.03M	542.6M	614.82M	455.87M	439.46M	424.49M	378.3M	205.59M	182.97M
Common Stock	363K	367K	370K	372K	374K	377K	380K	382K	385K	385K
Retained Earnings	-16.02M	-11.01M	5.13M	66.47M	-100.32M	-131.87M	-158.41M	-210.85M	-395.2M	-429.2M
Treasury Stock	-2.1M	-5.71M	-5.71M	-5.71M	-5.71M	-5.71M	-5.71M	-5.71M	-5.71M	-7.38M
Accumulated OCI	-791K	-1.32M	-952K	-1.35M	-1.34M	3.15M	1.36M	-4.72M	-4.37M	-2.02M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	May 2016	May 2017	May 2018	May 2019	May 2020	May 2021	May 2022	May 2023	May 2024	May 2025
Cash from Operations+	45.22M	55.74M	41.29M	37.44M	-14.55M	24.09M	-7.19M	78K	-28.16M	-10.13M
Operating CF Margin %	0.13%	0.16%	0.12%	0.1%	-0.06%	0.08%	-0.02%	0%	-0.09%	-0.03%
Operating CF Growth %	0.76%	0.23%	-0.26%	-0.09%	-1.39%	2.66%	-1.3%	1.01%	-362%	0.64%
Net Income	-44.45M	7.01M	16.34M	61.34M	-156.07M	-31.55M	-26.55M	-52.44M	-184.35M	-33.99M
Depreciation & Amortization	28.38M	24.81M	23.16M	25.88M	23.8M	25.92M	29.35M	30.87M	27.71M	25.8M
Stock-Based Compensation	3.24M	6.18M	7.91M	9.25M	7.59M	8.63M	10.69M	11.16M	10.53M	9.77M
Deferred Taxes	39.98M	4.43M	-8.95M	-2.65M	-1.57M	-4.8M	-3.71M	-2.31M	-7.97M	-988K
Other Non-Cash Items	4.61M	-9.54M	364K	-55.11M	140.23M	16.83M	4.07M	19.83M	111.5M	3.39M
Working Capital Changes	12.86M	24.86M	2.46M	-1.26M	-28.55M	9.07M	-21.05M	-7.03M	14.42M	-14.11M
Change in Receivables	3.13M	8.48M	5.04M	-3.18M	11.92M	-4.16M	-17.15M	-1.3M	7.89M	23K
Change in Inventory	11.98M	687K	5.74M	-1.43M	-18.84M	11.54M	-2.8M	-8.2M	-9.41M	-1.35M
Change in Payables	-3.4M	17.21M	-7.09M	5.21M	-15.47M	4.88M	3.91M	2.14M	27.53M	-15.88M
Cash from Investing+	-7.57M	-2.55M	-3.66M	82.55M	-63.34M	-13.71M	-19.31M	-9.75M	123.72M	-10.18M
Capital Expenditures	-2.33M	-3M	-2.39M	-3.12M	-7.24M	-5.19M	-4.3M	-3.81M	-2.52M	-4.46M
CapEx % of Revenue	0.01%	0.01%	0.01%	0.01%	0.03%	0.02%	0.01%	0.01%	0.01%	0.02%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-3.27M	0	-1.26M	169.24M	-350K	-8.52M	-11.41M	-5.93M	126.23M	-5.71M
Cash from Financing+	-23.66M	-37.98M	-11.55M	33.93M	-95.24M	-16.99M	7.68M	25.42M	-64.25M	-255K
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-7.41M	-516K	-6.55M	-6.07M	-2.74M	0	0	-751K	-15M	-4.75M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	39.62M	52.74M	37.63M	34.32M	-22.14M	18.91M	-11.49M	-4.27M	-33.93M	-14.59M
FCF Margin %	0.11%	0.15%	0.11%	0.1%	-0.08%	0.06%	-0.04%	-0.01%	-0.11%	-0.05%
FCF Growth %	2.06%	0.33%	-0.29%	-0.09%	-1.65%	1.85%	-1.61%	0.63%	-6.94%	0.57%
FCF per Share	1.10	1.43	1.00	0.92	-0.58	0.49	-0.29	-0.11	-0.84	-0.36
FCF Conversion (FCF/Net Income)	-1.04x	-7.90x	2.53x	0.61x	0.09x	-0.76x	0.27x	-0.00x	0.15x	0.30x
Interest Paid	3.06M	2.97M	3.19M	5.12M	413K	731K	562K	2.58M	0	185K
Taxes Paid	332K	102K	36K	426K	682K	313K	329K	342K	455K	800K

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-8.29%	-1.38%	3.08%	10.6%	-31.16%	-7.05%	-6.15%	-13.06%	-63.15%	-17.5%
Return on Invested Capital (ROIC)	0.12%	-1.42%	-1.87%	-1.3%	-25.95%	-6.2%	-5.08%	-9.28%	-54.21%	-22.93%
Gross Margin	49.29%	41.17%	41.78%	43.4%	56.89%	53.88%	52.41%	51.44%	50.9%	53.92%
Net Margin	-12.32%	-2.02%	4.74%	17.06%	-63.14%	-10.84%	-8.4%	-15.48%	-60.66%	-11.62%
Debt / Equity	0.26x	0.20x	0.17x	0.22x	0.09x	0.05x	0.08x	0.17x	0.02x	-
Interest Coverage	0.30x	-3.94x	-4.63x	-1.84x	-184.23x	-40.98x	-41.38x	-18.94x	-	-
FCF Conversion	-1.04x	-7.90x	2.53x	0.61x	0.09x	-0.76x	0.27x	-0.00x	0.15x	0.30x
Revenue Growth	-0.92%	-1.14%	-1.53%	4.41%	-26.52%	10.17%	8.66%	7.13%	-10.28%	-3.76%

Revenue by Segment

	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Med Device	-	-	-	-	-	-	237.5M	-	197.51M	-
Med Device Growth	-	-	-	-	-	-	-	-	-	-
Med Tech	-	-	-	-	-	-	78.72M	-	106.4M	-
Med Tech Growth	-	-	-	-	-	-	-	-	-	-
Endovascular Therapies	-	-	-	-	-	135.08M	-	-	-	-
Endovascular Therapies Growth	-	-	-	-	-	-	-	-	-	-
Oncology Surgery	48.9M	44.56M	49.19M	-	57.15M	54.62M	-	-	-	-
Oncology Surgery Growth	-	-8.87%	10.39%	-	-	-4.43%	-	-	-	-
Peripheral Vascular	202.78M	208.6M	202.33M	-	112.71M	-	-	-	-	-
Peripheral Vascular Growth	-	2.87%	-3.00%	-	-	-	-	-	-	-
Access	99.38M	96.48M	92.76M	94.73M	94.3M	-	-	-	-	-
Access Growth	-	-2.91%	-3.86%	2.12%	-0.45%	-	-	-	-	-
Supply Agreement	2.84M	-	-	-	-	-	-	-	-	-
Supply Agreement Growth	-	-	-	-	-	-	-	-	-	-

Revenue by Geography

	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
UNITED STATES	283.52M	282.17M	273.33M	106.77M	98.97M	121.43M	146.88M	84.33M	251.49M	250.98M
UNITED STATES Growth	-	-0.48%	-3.13%	-60.94%	-7.31%	22.70%	20.96%	-42.58%	198.21%	-0.20%
International	-	-	-	-	-	-	-	-	52.43M	41.52M
International Growth	-	-	-	-	-	-	-	-	-	-20.82%
Non-US	-	-	-	13.13M	13.74M	13.65M	14.04M	12.36M	-	-
Non-US Growth	-	-	-	-	4.62%	-0.65%	2.87%	-12.03%	-	-

Frequently Asked Questions

Growth & Financials

AngioDynamics, Inc. (ANGO) reported $307.3M in revenue for fiscal year 2025. This represents a 39% increase from $221.8M in 2012.

AngioDynamics, Inc. (ANGO) saw revenue decline by 3.8% over the past year.

AngioDynamics, Inc. (ANGO) reported a net loss of $27.7M for fiscal year 2025.

Dividend & Returns

AngioDynamics, Inc. (ANGO) has a return on equity (ROE) of -17.5%. Negative ROE indicates the company is unprofitable.

AngioDynamics, Inc. (ANGO) had negative free cash flow of $9.3M in fiscal year 2025, likely due to heavy capital investments.